Trial reportPloS one2010
Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.
Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Body mass index and prostate cancer incidence: a comprehensive systematic review.Frontiers in oncology · 2026Pooled it
- Are the FTO Gene Polymorphisms Associated with Colorectal Cancer? A Meta-analysis.Journal of gastrointestinal cancer · 2021Pooled it
- Dairy Products: Is There an Impact on Promotion of Prostate Cancer? A Review of the Literature.Frontiers in nutrition · 2019Pooled it
- Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Pooled it
- Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study.Cancer causes & control : CCC · 2015Trial
- Role of NOncology reports · 2024Review
- Revealing the Catalytic Strategy of FTO.Chem catalysis · 2023Article
- m6A-TSHub: Unveiling the Context-specific mGenomics, proteomics & bioinformatics · 2023Article
- The emerging roles and mechanism of N6-methyladenosine (mFrontiers in pharmacology · 2023Review
- Quantifying the Contributions of Environmental Factors to Prostate Cancer and Detecting Risk-Related Diet Metrics and Racial Disparities.Cancer informatics · 2023Article
- Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review).Molecular medicine reports · 2022Review
- Article
- Comprehensive mutations analyses ofFrontiers in nutrition · 2022Article
- The Potential Role of N6-Methyladenosine (m6A) Demethylase Fat Mass and Obesity-Associated Gene (FTO) in Human Cancers.OncoTargets and therapy · 2020Review
- Association of Obesity-Related Genetic Variants (FTO and MC4R) with Breast Cancer Risk: A Population-Based Case-Control Study in Iran.Iranian journal of biotechnology · 2019Article
- Novel positioning from obesity to cancer: FTO, an mJournal of cancer research and clinical oncology · 2019Review
- Epitranscriptomics of cancer.World journal of clinical oncology · 2018Review
- m6ASNP: a tool for annotating genetic variants by m6A function.GigaScience · 2018Article
- IsOncotarget · 2017Article
- The FTO rs9939609 polymorphism is associated with short leukocyte telomere length in nonobese individuals.Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
unlabelledObservational studies suggest that obese men have a lower risk of incident prostate cancer, but an increased risk of advanced and fatal cancers. These observations could be due to confounding, detection bias, or a biological effect of obesity. Genetic studies are less susceptible to confounding than observational epidemiology and can suggest how associations between phenotypes (such as obesity) and diseases arise. To determine whether the associations between obesity and prostate cancer are causal, we conducted a genetic association study of the relationship between a single nucleotide polymorphism known to be associated with obesity (FTO rs9939609) and prostate cancer. Data are from a population-based sample of 1550 screen-detected prostate cancers, 1815 age- and general practice matched controls with unrestricted prostate specific antigen (PSA) values and 1175 low-PSA controls (PSA <0.5 ng/ml). The rs9939609 A allele, which was associated with higher BMI in the sample, was inversely associated with overall (odds ratio (OR) versus all controls = 0.93; 95% confidence interval (CI): 0.85-1.02 p = 0.12 per allele) and low-grade (OR = 0.90; 0.81-0.99 p = 0.03 per allele) prostate cancer risk, but positively associated with high-grade cancer among cases (OR high- versus low-grade cancer = 1.16; 0.99-1.37 p = 0.07 per allele). Although evidence for these effects was weak, they are consistent with observational data based on BMI phenotypes and suggest that the observed association between obesity and prostate cancer is not due to confounding. Further research should confirm these findings, extend them to other BMI-related genetic variants and determine whether they are due to detection bias or obesity-related hormonal changes.
trial registrationControlled-Trials.com ISRCTN20141297.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.